Liquid biopsy is an exciting technology that is revolutionising the diagnosis and treatment of a range of disorders, in particular cancers. Whilst the concept of blood testing has become routine in medicine, liquid biopsy takes this idea to the next level to allow precision detection of disease, including at early stages or asymptomatic individuals. We have been involved in protecting liquid biopsy inventions since their emergence, including obtaining patents around non-invasive prenatal testing, circulating tumor nucleic acids, circulating tumor cells, diagnostic exosomes and proteomic liquid biopsy.

Inventions in liquid biopsy are often complex, with aspects of bioinformatics, genomics and diagnostics, and so building an effective global IP portfolio can be challenging. We have the expertise to draft applications that work around the world, and we’re experienced at managing prosecution of liquid biopsy inventions, working closely with our trusted international partners from an early stage to optimize success. Before the European Patent Office we’re not only successful in obtaining patents, but also have an enviable track record of success during opposition proceedings.

Inventions in this space often change dramatically over time, and we’re adept at managing IP at every stage of the journey, from initial biomarker discovery through to clinical validation and commercial launch.